Shanghai Fosun Pharmaceutical : VOLUNTARY ANNOUNCEMENT - LAPSE OF IMPLEMENTATION PERIOD OF THE SHAREHOLDING INCREASE PLAN

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

VOLUNTARY ANNOUNCEMENT

LAPSE OF IMPLEMENTATION PERIOD OF THE SHAREHOLDING

INCREASE PLAN

This announcement is made on a voluntary basis by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'').

Reference is made to the announcements of the Company dated 1 December 2020, 22 January 2021 and

24 May 2021 (the ''Announcements'') in relation to Shanghai Fosun High Technology (Group) Company Limited* (''Fosun High Tech''), the controlling shareholder of the Company, intention to increase its shareholding in the Company (including A Shares and/or H Shares) by way of, including but not limited to centralized price bidding or block trade at the stock exchanges, transfer by agreement by itself (and/or parties acting in concert with it) by itself and/or parties acting in concert with it during the 12 months commencing from 1 December 2020 (inclusive), for an aggregate amount of not less than RMB100 million (based on the middle exchange rates for Renminbi to Hong Kong dollars as announced by the People's Bank of China as at the respective date of shareholding increase, the same for below), and with the aggregate increased shareholding percentage not exceeding 2% of total issued shares of the Company as at 1 December 2020 (i.e. 2,562,898,545 shares, the same for below) and the aggregated number of shares in the Company to be acquired in the 12-month period shall not exceed 2% of the total number of issued shares in the Company (the ''Shareholding Increase Plan''). Unless otherwise specified, capitalized terms used herein shall have the same meaning ascribed to them in the Announcements.

- 1 -

1. THE IMPLEMENTATION OF THE SHAREHOLDING INCREASE PLAN
   The period of the implementation of the Shareholding Increase Plan lapsed on 30 November 2021 (after trading hours). From 1 December 2020 to 30 November 2021 (both dates inclusive), Fosun High Tech and Fosun International Limited (''Fosun International''), the controlling shareholder of Fosun High Tech, acquired an aggregate number of 27,930,500 H Shares for an aggregate amount of approximately RMB967 million with the increased shareholding percentage of Fosun High Tech and Fosun International in aggregate represents approximately 1.09% of the total issued shares of the Company as at 1 December 2020, and the aggregated number of shares in the Company acquired in the 12-month period did not exceed 2% of the total number of issued shares in the Company.
   As at 30 November 2021 (after trading hours), Fosun High Tech and Fosun International held an aggregate of 1,015,628,790 shares of the Company (including 938,095,290 A Shares and 77,533,500 H Shares), representing approximately 39.63% of the total issued shares of the Company as at 30 November 2021 (i.e. 2,562,898,545 shares).
   As at 30 November 2021 (after trading hours), Fosun High Tech and Fosun International did not reduce its shareholding in the Company during the implementation of the Shareholding Increase Plan and the statutory restricted period.

1. MISCELLANEOUS
   The implementation of the Shareholding Increase Plan complied with the provisions of the Securities Law of the People's Republic of China and other applicable laws, regulations, department regulations and the relevant rules of Shanghai Stock Exchange and The Stock Exchange of Hong Kong Limited.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

1 December 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non- executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

• For identification purposes only

- 2 -